

Seznam zdrojové a další literatury ke studiu

- [1] Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower tract function: report from the standardisation subcommittee of the International Continence Society. *Neurourol Urodyn* 2002;21(5):1670–1678.
- [2] Anderson KE. Alpha-adrenoreceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoreceptor antagonists. *Word J Urol* 2002;19(6):390.
- [3] Appell R, Sand P, Dmochowski R, et al. Prospective randomised controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of OBJECT study. *Mayo Clin Proc* 2001;76(2): 358–363.
- [4] Artibani W. Overactive bladder: new perspectives. *Eur Urol* 2002;Suppl. 4(1):1–30.
- [5] Baptista OM, Kusek JW, Nyberg LM, et al. Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. *Control Clin Trials* 2003;24:224–243.
- [6] Belej K. Prostatický syndrom – asymptomatická prostatitida. *Urologie Praxi* 2007;8(6):281–284.
- [7] Belej K. Transrektální sonografie v diagnostice onemocnění prostaty. *Urologie Praxi* 2009;10(1):363–366.
- [8] Berghmans L, Hendriks H, De Bie R, et al. Conservative treatment of urge urinary incontinence in women: a systematic review of randomized clinical trials. *BJU Int* 2000;85(2):254–263.
- [9] Bonkat G, Bartoletti RR, Bruyère F, et al. EAU Non-Oncology Guidelines. Dostupné z: <https://uroweb.org/individual-guidelines/non-oncology-guidelines/>.
- [10] Corona G, Rastrelli G, Morelli A, et al. Hypogonadism and metabolic syndrome. *J Endocrinol Invest* 2011;34(7): 557–567.
- [11] Cristoni A, Di Pierro F, Bombardelli E. Botanical derivatives for the prostate. *Fitoterapia* 2000;71 Suppl. 1:S21–8.
- [12] Dimitrakov JD, Kaplan SA, Kroenke K, et al. Management of chronic prostatitis/chronic pelvic pain syndrome: an evidence based approach. *Urology* 2006;67: 881–8.
- [13] Diokno A, Appell R, Sand P, et al. Prospective, randomised, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder. Results of the OPERA trial. *Mayo Clin Proc* 2003;78(4):687–695.
- [14] Ghazal M. Farmakoterapie LUTS/BPH v každodenní klinické praxi. Jak vybrat optimální alternativu? *Urol List* 2013;11(2): 12–24.
- [15] Hanuš T. *Urologie*. Praha: Triton, 2011.

- [16] Kempler P, Amarenco G, Freeman R, et al. Management strategies for gastrointestinal, erectile, bladder and sudomotor dysfunction in patients with diabetes. *Diabetes Metab Res* 2011;27: 655–677.
- [17] Kerrebroeck F, Haab F, Angulo J, et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose finding study (SATURN). *Eur Urol* 2013;64(6):398–407.
- [18] Kerrebroeck van P, Chapple C, Drogendijk T, et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. *Eur Urol* 2013;64(6):1003–1012.
- [19] Kladenský J, Pacík D. Infekce močových cest a jejich léčení. *Forum Medicinae* 2001;4:21.
- [20] Kladenský J, Pacík D. Nespecifické uroinfekce dospělých. *Postgrad Med* 2000;2:138.
- [21] Kolombo I, Klézl P, Grill R, Čapka D. Akutní stavy v urologii. Praha: Galén, 2016.
- [22] Kovářová D, Hlaváčová J, Dolejšová O, Stránský P, Bulka J, Hora M. Management poranění ledvin na Urologické klinice FN Plzeň. *Čes Urol* 2013;17(1):166–174.
- [23] Macek P, Hanuš T. Urologie: pro všeobecné praktické lékaře. Praha: Raabe, 2011.
- [24] Matoušková M. Zánětlivá onemocnění prostaty, postavení alfa-blokátorů v léčbě symptomů onemocnění. *Urologie Praxi* 2003;4:149–152.
- [25] McConell JD, for the MTOPS Steering Committee. The long term effects of medical therapy on the progression of BPH: results from MTOPS trial (Abstract 1042). *J Urol* 2002;167(4, Suppl.):265.
- [26] Michálek P, Kiška R, Sedláček J, Dobiáš M. Ultrazvukové vyšetření ledvin v perioperační medicíně a intenzivní péči. *Anest Intenziv Med* 2014;25(2):315–320.
- [27] Milson I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. *BJU Int* 2001;87:760–6.
- [28] Roehrborn CG, Bruskewitz R, Nickel GC, et al. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study Group. *Eur Urol* 2000;37:528–536.
- [29] Roehrborn CG, Kaminetsky JC, Auerbach SM, et al. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. *BJU Int* 2010;105(4):502–507.
- [30] Roehrborn CG, Malice MP, Cook TJ, et al. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: A comprehensive analysis of the pooled placebo groups of several large clinical trials. *Urology* 2001;58:210–216.
- [31] Roehrborn CG, McConnell JD, Saltzman B, et al. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. *Eur Urol* 2002;42:1–6.

- [32] Safarinejad MR. Urtica dioica for treatment for benign prostatic hyperplasia: a prospective, randomised, double-blind, placebo-controlled, crossover study. *J Herb Pharmacoter* 2005;5(4):1–11.
- [33] Seifert B, Vojtíšková J, Vitásek Z. Trendy v indikaci vybraných laboratorních metod všeobecnými praktickými lékaři. *Čas Lék Čes* 2016;155:116–120.
- [34] Shih SC, Bost JE, Pawlson LG. Standardized health plan reporting in four areas preventive health care. *AM J Prev Med* 2003;24(4):293–300.
- [35] Schneider T, Rübber H. Benneseltrockenextrakt (Bazoton-uno) in der Langezeittherapie des benignen Prostatasyndroms (BPS). Ergebnisse einer randomisierten, doppelblinden, placebokontrollierten Multicenterstudie über 12 Monate. *Urologe A* 2004;43(3):302–306.
- [36] Škulec R, Cmorej PCh, Durila M, Peřan D, et al. Curriculum urgentní ultrasonografie pro specialisty v oboru urgentní medicína. *Anesteziol Intenz Med* 2018;29(6):338–345.
- [37] Šrámková T. Poruchy sexuality u somatických onemocnění a jejich léčba. Praha: Grada Publishing, 2013.
- [38] Tamler R, Deveney T. Hypogonadism, erectile dysfunction, and type 2 diabetes mellitus: what the clinician needs to know. *Postgrad Med* 2010;122(6):165–175.
- [39] Türk C, Petřík A, Sarica K, et al. EAU Guidelines on diagnosis and conservative management of urolithiasis. *Eur Urol* 2016;69(3):468–474. doi: 10.1016/j.eururo.2015.07.040.
- [40] Vijayan AL, Vanimaya RS, et al. Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy. *J Intensive Care* 2017;5:51. doi: 10.1186/s40560-017-0246-8.
- [41] Vinarov AZ, Spivak LG, Platonova DV et al. 15 years' survey of safety and efficacy of *Serenoa repens* extract in benign prostatic hyperplasia patients with risk of progression. *Urologia Journal* 2019;86(1):17–22.
- [42] Wilt TJ, Ishani A, Rutks I, et al. Phytotherapy for benign prostatic hyperplasia. *Public Health Nutr* 2000;3(4A):459–72.